Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
$3.92
-6.2%
$6.44
$1.55
$10.95
$90.33M1.9114.89 million shs7.80 million shs
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$3.76
-3.5%
$3.28
$1.60
$15.04
$105.33M1.9183,411 shs55,611 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.05
+1.0%
$1.87
$0.79
$6.98
$46.20M0.488.11 million shs3.47 million shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.49
-2.3%
$0.53
$0.39
$3.75
$35.91M-0.02437,058 shs263,815 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
-6.22%-5.08%-34.01%-52.48%+79.82%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-3.25%-3.96%+19.21%+67.63%-72.43%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+0.96%+11.03%-55.13%-37.87%-83.77%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-2.34%-2.42%-11.29%-5.06%-79.41%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
$3.92
-6.2%
$6.44
$1.55
$10.95
$90.33M1.9114.89 million shs7.80 million shs
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$3.76
-3.5%
$3.28
$1.60
$15.04
$105.33M1.9183,411 shs55,611 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.05
+1.0%
$1.87
$0.79
$6.98
$46.20M0.488.11 million shs3.47 million shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.49
-2.3%
$0.53
$0.39
$3.75
$35.91M-0.02437,058 shs263,815 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
-6.22%-5.08%-34.01%-52.48%+79.82%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-3.25%-3.96%+19.21%+67.63%-72.43%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
+0.96%+11.03%-55.13%-37.87%-83.77%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-2.34%-2.42%-11.29%-5.06%-79.41%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
0.00
N/AN/AN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.57
Moderate Buy$8.50126.36% Upside
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.33
Hold$9.60814.29% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,403.04% Upside

Current Analyst Ratings Breakdown

Latest ALTS, RANI, OTLK, and ANRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/29/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
8/28/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyNeutral
8/27/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/18/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
8/15/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
6/26/2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
$12.53M6.76N/AN/A$0.49 per share8.00
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$5.62 per shareN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.51M30.98N/AN/A($3.09) per share-0.34
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M34.04N/AN/A$0.06 per share8.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
-$6.24MN/A0.00N/A-74.89%-179.27%-16.28%N/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$61.43M-$2.39N/AN/AN/AN/A-44.34%-36.73%11/11/2025 (Estimated)
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%11/13/2025 (Estimated)

Latest ALTS, RANI, OTLK, and ANRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q3 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million
8/13/2025Q2 2025
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.57-$0.65-$0.08-$0.65N/AN/A
8/7/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19-$0.18+$0.01-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
N/AN/AN/AN/AN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
1.45
0.88
0.88
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.18
18.43
18.43
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.67
0.54
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
6.27%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%

Insider Ownership

CompanyInsider Ownership
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
4.90%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.13%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALT5 Sigma Corporation stock logo
ALTS
ALT5 Sigma
17021.61 million20.55 millionN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A27.08 millionN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2044.42 million42.29 millionOptionable
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11071.87 million39.47 millionOptionable

Recent News About These Companies

RANI: Second Quarter Financial Results
Rani (RANI) Q2 Net Loss Improves 16%
Rani Therapeutics Holdings, Inc. (RANI) - Yahoo Finance
Rani Therapeutics strikes deal to issue new warrants
RANI: 1Q:25 Financial Results
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)
Rani Therapeutics management to meet virtually with Lake Street

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ALT5 Sigma stock logo

ALT5 Sigma NASDAQ:ALTS

$3.92 -0.26 (-6.22%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$4.02 +0.10 (+2.65%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$3.76 -0.14 (-3.47%)
Closing price 09/15/2025 03:59 PM Eastern
Extended Trading
$3.77 +0.02 (+0.43%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$1.05 +0.01 (+0.96%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$1.08 +0.03 (+2.86%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.49 -0.01 (-2.34%)
Closing price 09/15/2025 04:00 PM Eastern
Extended Trading
$0.47 -0.02 (-3.26%)
As of 05:45 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.